focus -WSS

focus

author：leisure time 2025-09-28 01:40:26 - browse：48576

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Dark money group runs ads on China biotech bill

WSS

California store owner shot dead in dispute over displaying Pride flag: Police

Republicans love RFK Jr. What's that tell us about health in 2024?

Trans patients at the end of life deserve respect and dignity

Kellogg’s is going to war over Mexico’s nutrition label rules

Startling documents reveal new facets of Sacklers' opioid empire

Akili, maker of video game for ADHD, to be acquired for 34 million

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Latest bird flu infection made farmworker sicker than earlier cases

Sports medicine is finally prioritizing gender equality

Meadows told special counsel he could not recall Trump ever declassifying Mar

New air purifier tech could be key to improving indoor air quality

Republicans love RFK Jr. What's that tell us about health in 2024?

How one medical school became remarkably diverse

Heat waves linked to early deliveries, preterm births in new study

Duchenne breakthrough therapy leaves behind pioneering families

Scientists successfully use ultrasound imaging to map brain activity

hotspot

People can get long Covid without testing positive for virus: Study

Akili, maker of video game for ADHD, to be acquired for 34 million

Average age of first period drops to 11.9 years, study shows

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

How the drug

Startling documents reveal new facets of Sacklers' opioid empire

leisure time

leisure time

explore

knowledge